Manufacturer
Pfizer
 
Contents
Olmesartan medoxomil 20 mg, hydrochlorothiazide 12.5 mg
 
Indication
ssential HTN in patients whose BP is inadequately controlled by olmesartan medoxomil or hydrochlorothiazide alone. 
 
Instruction
May be taken with or without food: Take at the same time each day. Swallow w/ sufficient amt of fluid (eg, 1 glass of water), do not chew.
 
Drug interaction
Increased serum lithium concentration & toxicity. Potentiation of antihypertensive effect w/ baclofen, amifostine. Reduce antihypertensive effect w/ NSAIDs. Increased BP-lowering effect w/ other antihypertensives. Potentiation of orthostatic hypotension by alcohol, barbiturates, narcotics or antidepressants. Olmesartan medoxomil: Increased serum K levels w/ K-sparing diuretics, K supplements, K-containing salt substitutes. Reduction in bioavailability by Al Mg hydroxide antacids. Hydrochlorothiazide: Potentiation of K-depleting effect w/ other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G Na or salicylic acid derivatives. Increase serum Ca levels. Impaired absorption by cholestyramine & colestipol resins. Favour onset of digitalis-induced cardiac arrhythmias. Periodic monitoring of serum K & ECG w/ class Ia & II antiarrythmics, antipsychotics, bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacin, terfenadine, vincamine IV. Potentiated effect of non-depolarizing skeletal muscle relaxants. Increased bioavailability by anticholinergics. Risk of lactic acidosis w/ metformin. Enhanced hyperglycemic effect of β-blockers. Decreased pressor amines effect. Raised serum uric acid levels. Increased risk of adverse effects by amantadine. Potentiation of myelosuppressive effects w/ cytotoxic agents. Enhanced toxic effects of salicylates. Increased risk of hyperuricemia & gout-type complications w/ cyclosporine. Increased risk of tetracycline-induced increase in urea.